MONDAY, Sept. 25, 2023 — For patients with metastatic breast cancer receiving the PI3K inhibitor alpelisib, hyperglycemia often occurs, with a median time to onset of 16 days, according to a study published online Sept. 25 in Cancer.
Sherry Shen,…Original Article
Many Receiving Alpelisib for Metastatic Breast Cancer Have Hyperglycemia
MONDAY, Sept. 25, 2023 — For patients with metastatic breast cancer receiving the PI3K inhibitor alpelisib, hyperglycemia often occurs, with a median time to onset of 16 days, according to a study published online Sept. 25 in Cancer.
Sherry Shen,…
